VIKRAMTHVikram Thermo (India) Ltd.
Vikram Thermo (India) Q2 FY27 Results: Standalone Net Profit ₹13.59 Crore on Total Income of ₹45.29 Crore
- Earnings
- Pharma polymers
Reviewed byKeshav SehgalBlacklitt Research
Vikram Thermo (India) (NSE: VIKRAMTH) reported standalone total income of ₹45.29 crore and net profit of ₹13.59 crore for the quarter ended 30 Sep 2026, it said in a filing on 04 Nov 2026.
Key highlights
Standalone
The company on its own, without its subsidiaries
- Total income: ₹45.29 crore, up 30.0% YoY and 16.9% QoQ
- Net profit and EPS: ₹13.59 crore, up 22.7% YoY; basic EPS ₹4.33 against ₹3.53
- Other income: ₹0.92 crore, against ₹0.21 crore a year earlier
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 45.29 | 34.85 | +30.0% | 38.76 | +16.9% | |
| Revenue from operations | 44.37 | 34.64 | +28.1% | 37.87 | +17.1% |
| Other income | 0.92 | 0.21 | +329.9% | 0.89 | +4.2% |
| 13.59 | 11.08 | +22.7% | 13.28 | +2.3% | |
| Profit before tax | 18.23 | 14.87 | +22.6% | 17.90 | +1.9% |
| Finance costs | 0.12 | 0.09 | +37.9% | 0.12 | +5.5% |
| Depreciation | 0.89 | 0.74 | +20.3% | 0.88 | +1.6% |
| Tax expense | 4.64 | 3.80 | +22.3% | 4.62 | +0.5% |
| Net profit margin | 30.00% | 31.78% | -1.78 pp | 34.27% | -4.26 pp |
| EPS, basic (₹) | 4.33 | 3.53 | +22.7% | 4.24 | +2.1% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Net profit grew more slowly than income. Total income rose 30.0% year on year, while net profit rose 22.7% and profit before tax rose 22.6%, with tax expense up 22.3% to ₹4.64 crore. The net profit margin fell from 31.78% to 30.00%.
Other income is a small part of the result. At ₹0.92 crore it is 2.0% of total income and 5.1% of profit before tax of ₹18.23 crore, so revenue from operations of ₹44.37 crore carries most of the quarter's income. Revenue from operations rose 28.1% year on year.
Finance costs of ₹0.12 crore are 0.3% of total income, and depreciation of ₹0.89 crore rose 20.3% year on year. The statement shows no exceptional items for the quarter.
The tax expense of ₹4.64 crore is 25.5% of profit before tax. The statement does not give a reason for the rise in other expenditure and employee benefit expense in the quarter.
Inference
The filing states that the company has no subsidiary, associate or joint venture as on 30 Sep 2026, and that its only reportable segment is Pharma Polymers. Paid-up equity share capital is ₹31.36 crore at a face value of ₹10 each.
The half-year dividend paid was ₹36.49 lakh, against ₹3.14 crore a year earlier. The filing does not say what dividend, if any, the board plans for the year, and it does not give a reason for the change in inventories line in the quarter.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
